On June 22, GenScript Biotech fell 8.14% in regular trading, trading at HK$10.79/share, with turnover of HK$104 million. The decline was triggered by a sharp sell-off in its associate company Legend Biotech on the US market the prior Friday.

Legend Biotech reportedly dropped 16.68% on NASDAQ, closing at $27.93, after conducting a discounted equity offering at $29.35 per share — approximately 12.4% below its prior closing price. The dilutive offering pressured Legend's stock below the placement price, and the negative sentiment subsequently transmitted to GenScript as its Hong Kong-listed parent. The proceeds from the offering are intended to fund pipeline development including LB2501 and general corporate purposes.

The broader Life Sciences Tools and Services sector also traded lower on the same day, with WUXI BIO down 3.24%, XTALPI down 3.93%, INSILICO down 3.18%, WUXI APPTEC down 0.93%, and WUXI XDC down 1.71%, reflecting broadly weak sentiment across the industry and amplifying selling pressure on GenScript.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)